ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma

Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state

(2017) Mohammad Fallahi‐Sichani et al.   Molecular Systems Biology

Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826).

(2017) P. N. Munster et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.

(2017) B. Grana et al.   JOURNAL OF CLINICAL ONCOLOGY

Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma

(2016) Wei Wei et al.   CANCER CELL

Resistance to Anti-VEGF Therapy Mediated by Autocrine IL6/STAT3 Signaling and Overcome by IL6 Blockade

(2016) Alexandra Eichten et al.   CANCER RESEARCH

Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells

(2016) Hui Ren et al.   Oncotarget

Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer

(2016) Tae-Hwe Heo et al.   Oncotarget

Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway

(2016) Pengfei Ma et al.   Theranostics

Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma

(2015) E. Massarelli et al.   ANNALS OF ONCOLOGY

Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors

(2015) David M. Hyman et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma

(2015) S. Mohan et al.   CLINICAL CANCER RESEARCH

Human mesenchymal stem cells enhance cancer cell proliferation via IL-6 secretion and activation of ERK1/2

(2015) AGMAL SCHERZAD et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer

(2015) Johan F. Vansteenkiste et al.   Journal of Thoracic Oncology

Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma

(2015) Aditya Stanam et al.   Molecular Oncology

A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer

(2015) Antonio Jimeno et al.   ORAL ONCOLOGY

Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells

(2015) Hui Zhang et al.   Oncotarget

An IL6-STAT3 loop mediates resistance to PI3K inhibitors by inducing epithelial–mesenchymal transition and cancer stem cell expansion in human breast cancer cells

(2014) Lin Yang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer

(2014) Jatin Roper et al.   CANCER LETTERS

Targeting the c-Met/FZD8 Signaling Axis Eliminates Patient-Derived Cancer Stem-like Cells in Head and Neck Squamous Carcinomas

(2014) S. Sun et al.   CANCER RESEARCH

Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck

(2014) Han Sang Kim et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies

(2014) C. M. Lovly et al.   CLINICAL CANCER RESEARCH

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

(2014) Jordi Rodon et al.   INVESTIGATIONAL NEW DRUGS

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

Differential involvement of gp130 signalling pathways in modulating tobacco carcinogen-induced lung tumourigenesis

(2014) A Miller et al.   ONCOGENE

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

(2014) M. Hidalgo et al.   Cancer Discovery

Oncogene Mimicry as a Mechanism of Primary Resistance to BRAF Inhibitors

(2014) Martin L. Sos et al.   Cell Reports

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

(2013) G. I. Shapiro et al.   CLINICAL CANCER RESEARCH

Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

(2013) Jyoti D. Patel et al.   JOURNAL OF CLINICAL ONCOLOGY

Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial

(2013) Robert Haddad et al.   LANCET ONCOLOGY

Tumor adaptation and resistance to RAF inhibitors

(2013) Piro Lito et al.   NATURE MEDICINE

What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-Kinase Pathway

(2013) S. J. Klempner et al.   Cancer Discovery

The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo

(2012) Hui Ren et al.   CANCER LETTERS

Interleukin-6 signaling pathway in targeted therapy for cancer

(2012) Yuqi Guo et al.   CANCER TREATMENT REVIEWS

Secrets of Drug Resistance in NSCLC Exposed by New Molecular Definition of EMT

(2012) D. S. Neel et al.   CLINICAL CANCER RESEARCH

A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

(2012) D. S. Hong et al.   CLINICAL CANCER RESEARCH

Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non-Small Cell Lung Cancer with T790M Resistance Mutation

(2012) S. M. Kim et al.   MOLECULAR CANCER THERAPEUTICS

Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

(2012) S. M. Brachmann et al.   MOLECULAR CANCER THERAPEUTICS

Role of Phosphatidylinositol-3-Kinase Pathway in Head and Neck Squamous Cell Carcinoma

(2012) Li Du et al.   Journal of Oncology

ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial Cells

(2011) Xuefeng Liu et al.   AMERICAN JOURNAL OF PATHOLOGY

Antitumor Activity of NVP-BKM120--A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells

(2011) D. Koul et al.   CLINICAL CANCER RESEARCH

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

IL-6 Promotes Head and Neck Tumor Metastasis by Inducing Epithelial-Mesenchymal Transition via the JAK-STAT3-SNAIL Signaling Pathway

(2011) A. Yadav et al.   MOLECULAR CANCER RESEARCH

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

(2011) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

The Mutational Landscape of Head and Neck Squamous Cell Carcinoma

(2011) N. Stransky et al.   SCIENCE

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

IL-6-induced Enhancement of c-Myc Translation in Multiple Myeloma Cells

(2010) Yijiang Shi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

(2010) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

MYCgene amplification reveals clinical association with head and neck squamous cell carcinoma in Indian patients

(2009) N. Bhattacharya et al.   JOURNAL OF ORAL PATHOLOGY & MEDICINE

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

(2009) James A Bonner et al.   LANCET ONCOLOGY

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies

(2008) Jan. B. Vermorken et al.   CANCER